Effect of telmisartan on sub-acute model of inflammation in male Wistar rats - an experimental study

Somnath M. Matule, Anil P. Hogade, Ranjit P. Kangle, Netravathi A. B., Rohan Kolla


Background: Cardiovascular diseases remain the major cause of death and premature disability in developed societies.Current predictions estimate that by the year 2020 cardiovascular diseases, notably atherosclerosis and hypertension will become leading global causes of total disease burden. The objective of the study was to investigate the influence of telmisartan on sub-acute model of inflammation in adult male Wistar rats.

Methods: After obtaining ethical clearance from Institutional Animal Ethics Committee, animals were allotted to the three groups i.e. control, aspirin and telmisartan (n=6 animals in each group). The effect of telmisartan on inflammation was studied using sub-acute (Cotton pellet granuloma and histopathologic examination of grass piths) models. Experiment was conducted according to the Committee for the purpose of Control and Supervision of Experiments on Animals (CPCSEA) guidelines. Analysis was done using one way ANOVA followed by post hoc tests of Dunnett’s and Bonferroni’s. P<0.05 was considered as statistically significant.

Results: In the present study telmisartan showed significant anti-inflammatory activity in sub-acute models of inflammation.

Conclusions: In view of role of inflammation in the pathogenesis of atherosclerosis and their complications, treatment by telmisartan can reduce complications by virtue of its anti-inflammatory activity, in addition to its antihypertensive effect. Also this study may help to open new avenues for therapeutic indications of telmisartan.



Telmisartan, Aspirin, Sub-acute inflammation, Foreign body granuloma

Full Text:



Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL et al. Harrison’s principles of internal medicine. 17th edition. New York: McGraw Hill Publishers; 2008;1501,1549,1552.

Park K. Park’s textbook of preventive and social medicine. 20th edition. Jabalpur: M/s Banarsidas Bhanot Publishers; 2009;325.

Seiko M, Takafumi O, Sanae W, Tokikazu F, Jitsuo H. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertesion. J Cardiovasc Pharmacol. 2005;46(6):735-9.

Dalekos GN, Elisaf MS, Papagalanis N, Tzallas C, Siamopoulos KC. Elevated interleukin-1β in the circulation of patients with essential hypertension before any drug therapy: a pilot study. Eur J Clin Invest. 1996;26(10):936-9.

Paresh D, Vikramjeet K, Ahmad A, Husam G, Tufail S, Debborah H et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-κB, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab. 2003;88(9):4496-501.

Kumar V, Abbas AK, Fausto N, Aster JC. Robbins and Cotran pathologic basis of diseases.8th edition. Philadelphia: Elsevier Publishers. 2010;500.

Matule SM, Hogade AP, Kangle RP, Torgal SS, Kothari N. Effect of telmisartan on acute model of inflammation in male Wistar rats: an experimental study. Int J Res Med Sci. 2016;4:135-8.

Laurence DR, Bacharach AL. Evaluation of Drug Activities: Pharmacometrics. New York and London: Academic Press Inc; 1964(2).

Sweetman SC. Martindale The Complete Drug Reference. 36th Edition. London: Pharmaceutical Press. 2009;23,1316,1409,1420.

Patil PA, Kulkarni DR. Effect of anti-proliferative agents on healing of dead space wounds in rats. Ind J Med Res 1984;79:445-7.

Kubo A, Fukuda N, Soma M, Izumi Y, Kanmatsuse K. Inhibitory effect of angiotensin II type 1 receptor antagonist on growth of vascular smooth muscle cells from spontaneously hypertensive rats. J cardiovasc Pharmacol. 1996;27(1):58-63.

Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE):a randomized trial against atenolol. Lancet. 2002;359(9311):995-1003.

von zur Muhlen B, Kahan T, Hagg A, Millgard J, Lind L. Treatment with irbesartan or atenolol improves endothelial function in essential hypertension. J Hypertens. 2001;19(10):1813-8.

Tian Q, Miyazaki R, Ichiki T, Imayama I, Inanaga K, Ohtsubo H et al. Inhibition of tumor necrosis factor factor-alpha induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator activated receptor gamma with nuclear factor kappa B and CCAAT/enhancer-binding protein-beta. Hypertension. 2009;53(5):798-804.

Fliser D, Buchholz K, Haller H. Anti-inflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004;110:1103-7.

Toshihiro I, Quingping T, Ikuyo I, Kenji S. Abstract 5249:Telmisartan manifests powerful anti-inflammatory effects beyond class effects of angiotensin II type-1 blocker by inhibiting tumor necrosis factor α – induced interleukin 6 expression through peroxisome proliferator activated receptor γ activation. Circulation. 2008;118:S513.

Silvana C, Alessandra DF, Renato C, Rossella DS, Ferdinando F, Roberto P. Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis. 2008;198(1):22-8.

Scheidegger KJ, Buttler S, Witztum JL. Angiotensin II increases macrophage mediated modification of low density liprotein via a lipoxygenase-dependent pathway. J Biol Chem. 1997;272(34):21609-15.